Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis of Crohn's disease or Ulcerative Colitis, proven by a biopsy
- People who are 18 years of age or older
- People who have elevated levels of a gut inflammation marker (fecal calprotectin or CRP) on a blood or stool test, or who score 50 or above on a fatigue measurement scale called the PROMISE Fatigue scale
- People who have been taking a stable dose of a biologic medication, an immunomodulator, or a 5-ASA medication for at least 12 weeks
Who may not be able to join:
- People whose IBD is currently very active, based on specific symptom scoring tools used by doctors (confirm with trial site)
- People with major depression, based on a score of 21 or higher, or any indication of suicidal thoughts, on the Beck Depression Inventory
- People considered high risk for sleep apnea, based on scoring high risk in two or more categories of a questionnaire called the Berlin Questionnaire
- People with restless leg syndrome, based on a score of 15 or higher on the IRLS Study Group Rating Scale
- People who have regularly used certain medications in the four weeks before the study, including metoclopramide, anti-inflammatory pain relievers (NSAIDs), beta blockers, psychiatric medications, sleeping tablets, or melatonin supplements
- People who have worked night shifts or travelled across more than two time zones in the month before the study
- People with significant kidney, liver, heart, or diabetes-related conditions, based on specific test results reviewed by a doctor
- People who have been diagnosed with narrow-angle glaucoma or retinal eye disorders, or who showed symptoms suggesting these conditions during screening
- People who are unable to sign an informed consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ali Keshavarzian, M.D., Rush University Medical Center
Phone: (312) 563-4981
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Changes in intestinal permeability (% excretion of urinary sucralose); Changes in microbiota will be assessed using shotgun metagene sequencing and total microbial community DNA
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.